Corvus Pharmaceuticals, Inc.
CRVS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $3 | $15 | $5 | $9 |
| Short-Term Investments | $63 | $60 | $39 | $43 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $1 | $1 | $1 | $2 |
| Total Curr. Assets | $67 | $76 | $45 | $54 |
| Property Plant & Equip (Net) | $1 | $1 | $1 | $1 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $12 | $12 | $12 | $13 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $1 | $1 | $1 |
| Total NC Assets | $14 | $14 | $14 | $15 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $80 | $89 | $59 | $69 |
| Liabilities | – | – | – | – |
| Payables | $2 | $3 | $1 | $3 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $6 | $5 | $8 | $33 |
| Total Curr. Liab. | $8 | $9 | $9 | $35 |
| LT Debt | $1 | $1 | $1 | $1 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $1 | $1 | $1 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $1 | $1 | $1 |
| Total Liabilities | $9 | $9 | $10 | $36 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$400 | -$390 | -$382 | -$397 |
| AOCI | -$1 | -$1 | -$1 | -$1 |
| Other Equity | $473 | $471 | $432 | $431 |
| Total Equity | $72 | $80 | $49 | $33 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $80 | $89 | $59 | $69 |
| Net Debt | -$2 | -$14 | -$4 | -$8 |